| Battling cancer, Jerry Yang is on leave from UConn's Center for Regenerative Biology. Read the story by William Hathaway in the Hartford Courant. more |
| 11/8 5:00 pm - 7:00 pm. Connecticut Technology Council Innovation Pipeline Awards. Cocktails, networking, poster fair, awards presentation. New Haven Lawn Club, New Haven, CT. more |
| 11/13 3:30 pm - 6:00 pm. CURE and Yale OCR Present: Vascular Insights LLC. A BioHaven Entrepreneurship Seminar. Reception and networking to follow. Anlyan Center, Congress Avenue, New Haven, CT. Watch for details. |
| 12/4 4:00 pm - 5:00 pm. CURE Annual Meeting. Achillion Conference Room, 300 George Street, New Haven, CT. Watch for details. |
| 12/4 5:30 pm - 7:30 pm. CURE Holiday Party. Café George, 300 George Street, New Haven. "New Haven's best holiday networking event." Watch for details. |
| 2/20 3:00 pm - 6:00 pm. CURE and Yale OCR Present: Rib-X. A BioHaven Entrepreneurship Seminar. Anlyan Center, Congress Avenue, New Haven, CT. Reception and networking to follow. Watch for details. |
| 3/19 3:00 pm - 6:00 pm. CURE and Yale OCR Present: Optherion. A BioHaven Entrepreneurship Seminar. Anlyan Center, Congress Avenue, New Haven, CT. Reception and networking to follow. Watch for details. |
| 3/26 Connecticut Innovations Annual Technology Celebration. The Aqua Turf Club, Southington, CT. more |
| 4/16 3:30 pm - 6:00 pm. CURE and Yale OCR Present: The Next Big Idea - Creating a New Venture. A Special BioHaven Entrepreneurship Panel with Roger Longman of Windhover Publications. Reception and networking to follow. Anlyan Center, Congress Avenue, New Haven, CT. Watch for details. |
| 4/23 3:00 pm - 6:00 pm. CURE and Yale OCR Present: Vidus Ocular. A BioHaven Entrepreneurship Seminar. Anlyan Center, Congress Avenue, New Haven, CT. Reception and networking to follow. Watch for details. |
|  |
|
|
Stem Cell Decision Continues to Pay Dividends
From the desk of Paul Pescatello, President and CEO of CURE
 The State of Connecticut’s wise decision to provide public funding for stem cell research continues to pay dividends in terms of the science and investment it has attracted to the state. Recently both Yale and UConn announced new stem cell facilities, and in the second year of the state's grant program, requests for funding have increased. Moreover, a recent tour of UK stem cell facilities by an official Connecticut delegation confirms that Connecticut is on the international map for this emerging area of bioscience activity.
For the full story
|
New Amistad Facility Houses Yale's State-of-the-Art Stem Cell Research
 Yale School of Medicine Oct 5 celebrated the opening of a new four-story building on Amistad Street that will house three interdisciplinary research programs. They are a human and translational immunology program, a program in vascular biology and therapeutics, and the Yale Stem Cell Center.
For the full story
|
University of Connecticut Creates Stem Cell Institute
The University of Connecticut’s board of trustees has officially approved creation of a Stem Cell Institute that will unite two major UConn programs,  the Center for Regenerative Biology in Storrs, and the Department of Department of Genetics and Developmental Biology and Center for Regenerative Medicine and Skeletal Development at the UConn Health Center in Farmington. Also housed in the Institute will be the Stem Cell Core, a program funded by state grants to UConn and Wesleyan University that creates and banks human embryonic stem cell lines for use by qualified researchers in Connecticut and beyond.
For the full story
|
Life Sciences Get Top Share of VC Funding in 3Q
According to the MoneyTree™ Report, six Connecticut companies received $26.8 million in venture capital funds during the third quarter of 2007. The largest investments went to life sciences sector companies Optherion, Inc. of Branford and HistoRx of New Haven.
For the full story
|
CURE in the News
CURE has been cited numerous times in the media the past six months. Stories range from the BioBus “going green” to the “rediscovery” of Connecticut by venture capitalists.
For the full story
|
CURE Member News Digest
 Achillion reports elvucitabine results
Bayer HealthCare sees positive macular degeneration results
Boehringer Ingelheim and Vitae to study diabetes compound
Bristol-Myers Squibb and ImClone to treat colorectal cancer
Connecticut Innovations names Peter Longo president
CuraGen discontinues velafermin
GlaxoSmithKline names Witty president designate
Hartford Hospital hosts pandemic rehearsal
HistoRx gets $6.6 million in second round
Invitrogen and Blue Heron offer gene synthesis
Ipsogen gets $680,000 follow-on investment
Johnson & Johnson reports REMICADE® progress
Neurogen names Kenneth Sprenger VP clinical development
Optherion gets $37 million in financing
Pfizer to discontinue Exubera
New president of Wesleyan University in Hartford Courant article
UConn researchers tap tobacco money
Yale gets $15 million for health study
For the full story
|
|
|
